Literature DB >> 10669327

Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States.

P S Sullivan1, A N Do, D Ellenberger, C P Pau, S Paul, K Robbins, M Kalish, C Storck, C A Schable, H Wise, C Tetteh, J L Jones, J McFarland, C Yang, R B Lal, J W Ward.   

Abstract

A population-based surveillance registry was used to identify human immunodeficiency virus (HIV)-infected persons in the United States at increased risk for group O and group N infections (those born in or near African countries where group O infection has been reported). Of 155 eligible subjects, 37 gave samples. By phylogenetic and serologic analysis, 32 were infected with group M (16 with subtype A, 5 with B, 7 with C, and 1 each with subtypes D, F2, G, and recombinant A/J) and 2 with group O but none with group N virus. For 3, samples could not be typed by serology or amplified by polymerase chain reaction using group M-, O-, or N-specific primers. In the United States, group O HIV infection is uncommon; no case of group N infection was found. African-born persons may have HIV strains typical of their birth country. Ongoing subtype surveillance may allow early identification of novel or emerging HIV strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669327     DOI: 10.1086/315254

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants.

Authors:  W H Koch; P S Sullivan; C Roberts; K Francis; R Downing; T D Mastro; J Nkengasong; D Hu; S Masciotra; C Schable; R B Lal
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  The Changing Epidemic of HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Authors:  Mohan Kumar Haleyur Giri Setty; Jikun Liu; Prerna Mahtani; Panhe Zhang; Bingchen Du; Viswanath Ragupathy; Krishnakumar Devadas; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

Review 5.  Non-M variants of human immunodeficiency virus type 1.

Authors:  Thomas Mourez; François Simon; Jean-Christophe Plantier
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

6.  A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo.

Authors:  Christophe Vanpouille; Jean A Bernatchez; Andrea Lisco; Anush Arakelyan; Elisa Saba; Matthias Götte; Leonid Margolis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

7.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

8.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains.

Authors:  Kenneth E Robbins; Philippe Lemey; Oliver G Pybus; Harold W Jaffe; Ae S Youngpairoj; Teresa M Brown; Marco Salemi; Anne-Mieke Vandamme; Marcia L Kalish
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120.

Authors:  Francesca Curreli; Dmitry S Belov; Shahad Ahmed; Ranjith R Ramesh; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  ChemMedChem       Date:  2018-10-19       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.